BioNxt Solutions Inc. (BNXTF) News
Follow BioNxt Solutions Inc. (BNXTF) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BioNxt Completes GMP Manufacturing, Submits Clinical Trial Application
BioNxt completed GMP manufacturing and submitted a clinical trial application for its sublingual cladribine drug candidate.
EQUITY | Oct 19, 2026, 07:05 AM UTC
L
BioNxt advances sublingual everolimus ODF; large-animal PK study begins
BioNxt is advancing its sublingual everolimus ODF for organ transplant rejection and has initiated a large-animal pharmacokinetic study.
EQUITY | Sep 08, 2026, 07:05 AM UTC
L
BioNxt Solutions closes convertible debenture extension; issues warrants
BioNxt Solutions Inc. announces the closing of an extension of convertible debentures and the issuance of warrants, according to TradeXchange Newsdesk.
MNA | Aug 21, 2026, 10:30 PM UTC
L
BioNxt provides development and IP update across sublingual pipeline
BioNxt (BNXTF) issues a development, intellectual property, and commercial update across its sublingual drug delivery pipeline.
EQUITY | Aug 17, 2026, 10:40 AM UTC
M
BioNxt Updates Sublingual Drug Pipeline
BioNxt provides development update
EQUITY | Aug 04, 2026, 07:05 AM UTC
L
BioNxt Solutions Announces Option Grants
BioNxt Solutions grants options
EQUITY | Jul 31, 2026, 10:26 PM UTC
L
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
VANCOUVER, BC / / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:B
EQUITY | Jul 06, 2026, 07:05 AM UTC
L
BNXT: Closes Private Placement
BioNxt announces closing of non-brokered private placement of units
EQUITY | Jun 23, 2026, 09:20 PM UTC